New Delhi, August 29, 2016: Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that it has received Abbreviated New Drug Application (ANDA) final approval for Telmisartan Tablets, USP 20,40 and 80mg, the generic version of Micardis® Tablets of Boehringer Ingelheim Pharmaceuticals Inc., which is used for the treatment of hypertension.
As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe.
Corporate Comm India(CCI Newswire)
Mumbai, May 22, 2024: The Department of Nursing at S.L. Raheja Hospital, Mahim - A…
Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…